Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.
Drug resistance is a major obstacle in the treatment of cancers. In an aggressive type of pancreatic cancer, for instance, drug resistance is associated with the suppression of programmed cell death, which results in the uncontrolled growth of cancer cells.
Lung cancer is the second leading cancer in the United States and the No. 1 cause of cancer-associated deaths.
Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.
Researchers generated a 3D pancreatic cancer tumor model in the lab, merging a bioengineered matrix and patient-derived cells.
MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas, using either healthy or cancerous pancreatic cells.
Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.
For many years, computer models have been standard tools in fundamental biomedical research.
A study headed by UCM reports that polymorphisms in gene TGFB1 and low plasma levels of protein TGFB1 serve as biomarkers for the gastric adenocarcinoma prognosis.
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients. This is the finding of a study with experiments in cancer cells, mice, and human tissue samples published online on November 2 in Cell.
Scientists have described the individual cells comprising the pancreatic cancer microenvironment.
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival. (1-3)
As cancer cells evolve, many of their genes become overactive while others are turned down. These genetic changes can help tumors grow out of control and become more aggressive, adapt to changing conditions, and eventually lead the tumor to metastasize and spread elsewhere in the body.
Baylor Scott & White Research Institute has received funding for a study from the National Institute of Biomedical Imaging and Bioengineering, one of the 27 institutes and centers of the National Institutes of Health (NIH), the nation's premier medical research agency.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent.
A team of Chinese scientists from the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, the State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and Shanghai Jiao Tong University, recently reported a comprehensive proteomic analysis based on 103 Chinese patients with lung adenocarcinoma (LUAD), a leading cause of death among all types of cancer worldwide.
Blocking a pair of sugar-transporting proteins may be a useful treatment approach for lung cancer, suggests a new study in mice and human cells published today in eLife.
Scientists have pioneered the use of whole living cells (that is, human lung adenocarcinoma) in dynamic combinatorial chemistry systems.
Pancreatic cancer cells use a normal waste removal process to hide tags on their surfaces that would otherwise let the immune system destroy them, a new study finds. Published online April 22 in Nature, the study results help to answer a longstanding question: why are pancreatic cancers so resistant to immunotherapies, which use the body's own immune defenses to fight cancer?